By Steve Edelson
Staff Writer

In 1997, Elan Corp. plc placed a $375 million bet on Sano Corp. in an acquisition designed to add late-stage products to ELN's pipeline and strengthen its transdermal drug delivery technology. One of those late-stage products - a smoking cessation patch - now looks unlikely to pan out, but the company believes that other products in the Sano pipeline will more than pay for the acquisition.